I got in touch with Jon Pilcher to comment on the diarrhea problem that a patient exhibited in your post,
and this is what Jon wrote back. all looks good iMOHi George,
Thanks for your e-mail. The entire safety and efficacy data from 180 patients is what approval will be based on. I can’t comment on individual experiences, both positive and negative (and the participants shouldn’t comment while Lavender is still running). As you know on Thursday we released the Q1 update confirming all is on track for Q4 results and highlighting the scale of Acadia’s commitment.
Kind regards, Jon
Jon Pilcher
Chief Executive Officer
Neuren Pharmaceuticals
- Forums
- ASX - By Stock
- NEU
- Ann: Quarterly report and cash flow statement for Q1 2021
Ann: Quarterly report and cash flow statement for Q1 2021, page-37
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.07 | 6644 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.990 |
1 | 300 | 13.970 |
1 | 400 | 13.960 |
3 | 2997 | 13.950 |
1 | 1828 | 13.930 |
Price($) | Vol. | No. |
---|---|---|
14.070 | 3070 | 3 |
14.080 | 323 | 2 |
14.100 | 1828 | 1 |
14.130 | 1828 | 1 |
14.150 | 1828 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |